This Wednesday is looking thinner than normal trading days for analyst upgrades and downgrades seen in Wall Street research calls. Here are today’s top calls: Apple Inc. (NASDAQ: AAPL) target was raised…
This morning’s top day trader and active trader alerts are below with links to VSInvestor.com on each stock story with more detailed data and analysis: Wells Fargo & Co. (NYSE: WFC) is…
These are the top ten analyst research initiations, upgrades, and downgrades we have seen from top Wall Street firms early this Wednesday morning: Biogen-Idec (BIIB) Started as Underperform at BofA/Merrill Lynch. Forest…
The following are some of the top stocks to watch for active trading today based on pre-market and after-hours volume activity. There are links through to more detailed coverage and volume analysis…
Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line data, a new biotech-based treatment, and a massive potential market. With help…
Here are some of today’s top stories affecting key drug and biotech stocks, accompanied with links through to more detailed information and analysis at BioHealthInvestor.com: New short-interest data suggest traders are now…
Novartis AG (NYSE: NVS) shares are at session highs and well of the lows of the day in the early afternoon Thursday after Japan okayed one of the company’s human growth hormones,…
Monday is looking like a SWINE FLU speculative flu stock stock bonanza, and we want to caution about some of the lessons of scares in the past of SARS, bird flu, Mad…
Gilead Sciences, Inc. (Nasdaq: GILD) has agreed to buy CV Therapeutics, Inc. (Nasdaq: CVTX) for $20.00 per share in cash.
Douglas A. McIntyre Biogen Idec Inc. (NASDAQ: BIIB) is set to report earnings on Friday morning. What many investors probably want to know is if these results — or more importantly its guidance — show…
There may be some speculation that drug giant Pfizer Inc. (NYSE: PFE) is looking at expansion through acquisitions. The FT reported that the world’s largest pharmaceutical company is willing to acquire a…
It is getting pretty thin in major analyst coverage as firms are encouraged to go easy on major year-end calls barring anything unexpected. These are the top analyst upgrades, downgrades, and new…
These are the top pre-market upgrades and positive analyst calls we have seen from Wall Street this Monday morning: Altria (NYSE: MO) Raised to Overweight at JPMorgan. Best Buy (NYSE: BBY) Raised…
It seems that short sellers have no real direction in the major NASDAQ biotech stocks from mid-November to late-November. Generally you see a pattern. This month the only pattern seems to be…
Gilead Sciences Inc. (NASDAQ: GILD) has just issued its third quarter earnings at $0.52 net EPS and $0.55 non-GAAP EPS and $1.37 billion in revenue. First Call had estimates at $0.49 non-GAAP…
Douglas A. McIntyre 